Express Scripts

Ginkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of Directors

Retrieved on: 
月曜日, 4月 29, 2024
Amazon (company), AstraZeneca, Public sector, University, AMZN, SAP SuccessFactors, AI, Climate, Fintech, Chairperson, Express Scripts, Genentech, Vant, Trustee, XYZ, Growth, Roivant Sciences, Engineering, DNA, Helmy Eltoukhy, Plumtree Software, Liberty Mutual, Bristol Myers Squibb, University of Chicago, Biology, Symantec, Merck, Biotechnology, Management

And I could not be more grateful to Marijn and Reshma for their leadership and guidance over this truly evolutionary period for Ginkgo.

Key Points: 
  • And I could not be more grateful to Marijn and Reshma for their leadership and guidance over this truly evolutionary period for Ginkgo.
  • Myrtle Potter brings over 25 years of experience leading and advising global technology and life sciences companies and serving on public company boards.
  • Until recently, Ms. Potter served as President, Chief Executive Officer, and Chair of the board of Sumitomo Pharma America.
  • Ross Fubini founded XYZ Venture Capital, a venture capital investment firm, in 2017, and serves as Managing Director.

Lark Health names a new Chief Growth Officer to scale GLP-1 cost containment and care offerings

Retrieved on: 
金曜日, 4月 12, 2024
Express Scripts, Weight loss, Medicine, Entrepreneurship, Obesity, Patient, Lark Health, Therapy

Lark Health is a leading provider of weight management and cardiometabolic care for employers and health plans— serving nearly 2.5 million patients and more than 2000 employers.

Key Points: 
  • Lark Health is a leading provider of weight management and cardiometabolic care for employers and health plans— serving nearly 2.5 million patients and more than 2000 employers.
  • Lark names a new Chief Growth Officer, Darren Eckberg, to lead the expansion of its AI, GLP-1 cost containment programs.
  • "I'm honored to be joining the Lark team and am thrilled to help millions of Americans struggling with a chronic condition.
  • Lark's current GLP-1 offerings include comprehensive services designed to achieve a 77% reduction in GLP-1 costs, while simultaneously optimizing population health outcomes.

HealthTrackRx Appoints Leading Healthcare Expert Dr. Steven Goldberg as Chief Medical Officer

Retrieved on: 
火曜日, 4月 9, 2024
Diagnosis, PCR, Medicine, Infection, Coventry Health Care, Thomas Jefferson University, Partnership, Georgetown University, Greater Louisville Inc., Humana, Standard of care, MD, MBA, Quality, WellCare, Express Scripts, Approximation error, Region, Kaiser Permanente, CMO, Binghamton University, Quest Diagnostics

DENTON, Texas, April 9, 2024 /PRNewswire/ -- HealthTrackRx, the nation's premier molecular diagnostic testing laboratory, today announced the appointment of Steven Goldberg, MD, MBA, as its Chief Medical Officer (CMO).

Key Points: 
  • DENTON, Texas, April 9, 2024 /PRNewswire/ -- HealthTrackRx, the nation's premier molecular diagnostic testing laboratory, today announced the appointment of Steven Goldberg, MD, MBA, as its Chief Medical Officer (CMO).
  • In the newly created role, Dr. Goldberg will lead the Company's partnership with payors, clinicians, and industry to enhance access to faster, better diagnostics.
  • A distinguished physician and respected healthcare innovator, Dr. Goldberg previously served as Chief Health Officer and Vice President of Medical Affairs at Quest Diagnostics and, preceding that, more than a decade in leading roles of several major health plans, including Chief Medical Officer at WellCare Health Plans, Senior Medical Director at Coventry Health Care, Chief of Medical Affairs at Express Scripts, Corporate Medical Director, Clinical Policy and Quality at Humana, Regional Chief Medical Officer at Excellus BCBS, Network Medical Director at Aetna Health Plans, and Medical Director at Kaiser Permanente NE.
  • "HealthTrackRx is transforming antibiotic stewardship protocols and helping payors and health plans manage spending by eliminating unnecessary tests, misdiagnosis, and ineffective antibiotic treatment.

Orsini Announcement: Orsini Specialty Pharmacy Welcomes Two Executive Leadership Hires

Retrieved on: 
木曜日, 4月 4, 2024
Haddock, Growth, CFO, Eisai, Patient, ELK, Pharmacy, University, Senior, Express Scripts, IQVIA, Economics, Management

ELK GROVE VILLAGE, III., April 4, 2024 /PRNewswire/ -- Orsini Specialty Pharmacy is pleased to announce that it has welcomed Victor Haddock as its new Chief Financial Officer and Lynda Parker as Executive Vice President of Trade Relations and Account Management.

Key Points: 
  • ELK GROVE VILLAGE, III., April 4, 2024 /PRNewswire/ -- Orsini Specialty Pharmacy is pleased to announce that it has welcomed Victor Haddock as its new Chief Financial Officer and Lynda Parker as Executive Vice President of Trade Relations and Account Management.
  • Orsini Specialty Pharmacy welcomes Victor Haddock and Lynda Parker to Executive Leadership Team.
  • Haddock has over 25 years of financial leadership experience in the healthcare sector, with a demonstrated ability to lead business strategies, implement change and build successful teams.
  • He most recently served as CFO of Triple-S Management in Puerto Rico, and he has held leadership positions at MagellanRx and Express Scripts.

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
木曜日, 3月 7, 2024
Esophagus, Hercules, Pharmacy, Quarter, Research, Heartburn, DUAL, Regulation, Forecasting, FDA, Pain, Table, PDUFA, Vomiting, Inflammation, GERD, Ratio, PPI, GAAP, Business, Webcast, Enzyme inhibitor, Patient, Express Scripts, Helicobacter pylori, Clinical trial, Vonoprazan/amoxicillin, PBM, G&A, Eosinophilic esophagitis, Tablet, NDA, Prescription, Vonoprazan/amoxicillin/clarithromycin, Pharmaceutical industry

Net loss: Net loss for the fourth quarter 2023 was $79.6 million, compared to $55.0 million for fourth quarter 2022.

Key Points: 
  • Net loss: Net loss for the fourth quarter 2023 was $79.6 million, compared to $55.0 million for fourth quarter 2022.
  • Fourth quarter 2023 net loss included a non-cash charge related to stock-based compensation of $24.6 million compared to $6.7 million for fourth quarter 2022.
  • Phathom will host a conference call and webcast to discuss its fourth quarter and full year 2023 financial results and business highlights today, March 7, 2024, at 8:30 a.m.
  • Phathom believes the presentation of these non-GAAP financial measures provides useful information to management and investors regarding Phathom's results of operations.

Local Pharmacies on the Brink, New Survey Reveals

Retrieved on: 
火曜日, 2月 27, 2024
Pharmacy, DIR, CMS, Part, Thought, Sale, MBA, Letter, Pharmacist, Hardship, Human, Medicare, Patient, Tax, Express Scripts, Medicare Part D, CVS, NCPA, Congress, PBM, Caremark, Community, CBO, Prescription, Insurance, Pressure, Health insurance

The rule is intended to give pharmacies and patients more transparency on drug pricing.

Key Points: 
  • The rule is intended to give pharmacies and patients more transparency on drug pricing.
  • According to the new NCPA survey, 32 percent of all respondents say they are considering closing their doors in 2024 because of the cash crunch.
  • Increased vertical and horizontal consolidation of PBMs and health plans has caused severe inequities to pharmacies and Medicare Part D beneficiaries alike.
  • Community pharmacies are rooted in the communities where they are located and are among America’s most accessible health care providers.

New Data Published by Omada Health Demonstrates the Impact of Coupling GLP-1s and Behavior Change Programming

Retrieved on: 
金曜日, 3月 8, 2024
Diabetes, Health, Cardiology, Telemedicine, Virtual Medicine, Obesity, Cardiovascular disease, Weight loss, Hope, Health care, Hypertension, Prediabetes, Express Scripts, Partnership

The Omada program is designed to help bolster the weight loss of EncircleRx members using GLP-1 medications for weight management.

Key Points: 
  • The Omada program is designed to help bolster the weight loss of EncircleRx members using GLP-1 medications for weight management.
  • The retrospective analysis found that individuals in the Omada for Prevention program who were using GLP-1s for weight loss had statistically better results when highly engaged in the Omada behavior change program.
  • Omada Health is a virtual-first healthcare provider that nurtures lifelong health, one day at a time.
  • Omada care teams implement clinically validated behavior change protocols for individuals living with diabetes, hypertension, prediabetes, weight health and musculoskeletal issues.

Vimly Benefit Solutions Announces Strategic Hire to Further Enable Growth

Retrieved on: 
水曜日, 3月 6, 2024
Software, General Health, Professional Services, Internet, Data Management, Payments, Technology, Small Business, Health Technology, Health Insurance, Insurance, Human Resources, Health, Acquisition, Professional, Multimedia, Marketing, Growth, Express Scripts, Management

Vimly Benefit Solutions (“Vimly”), a leader in the benefits administration space, has announced the addition of Marc Palmer as the new Chief Commercial Officer.

Key Points: 
  • Vimly Benefit Solutions (“Vimly”), a leader in the benefits administration space, has announced the addition of Marc Palmer as the new Chief Commercial Officer.
  • View the full release here: https://www.businesswire.com/news/home/20240306771714/en/
    “As Vimly continues to execute its growth strategy and follow up on our strategic majority investment from Rubicon Technology Partners, it became clear that we needed someone like Marc,” said Shannon Jurdana, CEO at Vimly.
  • Palmer was also CEO of ConnectYourCare and inVentiv Health and Chief Operating Officer at SS&C Health and Stonebrook Risk Solutions.
  • “I am impressed by the level of talent and professionalism and the foundation the Vimly team has built.

Healthcare Veteran and Former Navitus Executive, Byron Mickle, joins HealthPlan Data Solutions (HDS) as Chief Growth Officer

Retrieved on: 
木曜日, 2月 15, 2024
Technology, Payments, Health Technology, Health Insurance, Software, Other Health, Pharmaceutical, Health, Data Management, Artificial Intelligence, Pharmacy, Senior, AI, HDS, Growth, University, Family, Express Scripts, Business administration, PBM

Today HealthPlan Data Solutions, Inc. (HDS) announced the hire of Byron Mickle as the company’s Chief Growth Officer, effective February 4.

Key Points: 
  • Today HealthPlan Data Solutions, Inc. (HDS) announced the hire of Byron Mickle as the company’s Chief Growth Officer, effective February 4.
  • Byron is a seasoned healthcare executive with nearly four decades of experience working with health insurance and pharmacy benefit management (PBM) companies including Medco Health, Express Scripts, and Navitus Health Solutions.
  • In addition to his corporate experience, Byron has also served as a board participant for over 15 years.
  • Prior to joining HDS, Mickle served as a Senior Vice President and Chief Growth Officer for Navitus Health Solutions from 2007 to 2022.

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients

Retrieved on: 
火曜日, 2月 13, 2024
Urinary tract infection, Gastroesophageal reflux disease, Research, Heartburn, Toxicity, Magnesium, Polyp, Liver, CYP, CGA, Achlorhydria, Esophagitis, Patient, PBM, Vitamin B12, Vonoprazan, Kidney, Spine, Lactation, Absorption, Hypokalemia, SCAR, Calcium, Express Scripts, TIN, Endoscopy, Tablet, Express, Magnesium deficiency, Hypocalcemia, Diarrhea, Hypersensitivity, Physician, Gastritis, Malabsorption, GERD, PPI, Hypertension, SJS, Enzyme inhibitor, EGFR, Stevens–Johnson syndrome, Indigestion, Nelfinavir, Clostridioides, Abdominal pain, Hip, Pharmacy, Enzyme, Glomus tumor, FDA, CDAD, Atazanavir, Risk, BMJ Open, Wrist, Drug, Impairment, Pharmaceutical industry

Given that most Erosive GERD patients have already undergone treatment with a PPI, and many continue to express dissatisfaction with their current regimens, we are pleased with this outcome.

Key Points: 
  • Given that most Erosive GERD patients have already undergone treatment with a PPI, and many continue to express dissatisfaction with their current regimens, we are pleased with this outcome.
  • doi:10.1136/ bmjgast-2022-000941
    VOQUEZNA® (vonoprazan) is a potassium-competitive acid blocker (PCAB) indicated:
    for the healing of all grades of Erosive Esophagitis (Erosive Gastroesophageal Reflux Disease or Erosive GERD) and relief of heartburn associated with Erosive GERD in adults.
  • for the maintenance of healing of all grades of Erosive GERD and relief of heartburn associated with Erosive GERD in adults.
  • Renal Impairment: For the healing of Erosive GERD, dosage reduction is recommended in patients with severe renal impairment (eGFR